“Screening for prostate cancer has been a public health disaster,” announced Andrew J. Vickers, PhD, Attending Research Methodologist, Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York City. At the
Peter R. Carroll and Andrew J. Vickers
Rahul Aggarwal, Tian Zhang, Eric J. Small and Andrew J. Armstrong
and outcomes of NEPC Outline treatment options for patients with NEPC Neuroendocrine prostate cancer (NEPC) is a lethal form of prostate cancer, with most patients dying within 1 to 2 years of diagnosis. 1 , 2 Pure localized small cell carcinoma
James L. Mohler, Philip W. Kantoff, Andrew J. Armstrong, Robert R. Bahnson, Michael Cohen, Anthony Victor D’Amico, James A. Eastham, Charles A. Enke, Thomas A. Farrington, Celestia S. Higano, Eric Mark Horwitz, Christopher J. Kane, Mark H. Kawachi, Michael Kuettel, Timothy M. Kuzel, Richard J. Lee, Arnold W. Malcolm, David Miller, Elizabeth R. Plimack, Julio M. Pow-Sang, David Raben, Sylvia Richey, Mack Roach III, Eric Rohren, Stan Rosenfeld, Edward Schaeffer, Eric J. Small, Guru Sonpavde, Sandy Srinivas, Cy Stein, Seth A. Strope, Jonathan Tward, Dorothy A. Shead and Maria Ho
Prostate cancer has surpassed lung cancer as the most common cancer in men. Experts generally accept that these changes resulted from prostate-specific antigen (PSA) screening that detected many early-stage prostate cancers. An estimated 233,000 new cases
James Mohler, Robert R. Bahnson, Barry Boston, J. Erik Busby, Anthony D'Amico, James A. Eastham, Charles A. Enke, Daniel George, Eric Mark Horwitz, Robert P. Huben, Philip Kantoff, Mark Kawachi, Michael Kuettel, Paul H. Lange, Gary MacVicar, Elizabeth R. Plimack, Julio M. Pow-Sang, Mack Roach III, Eric Rohren, Bruce J. Roth, Dennis C. Shrieve, Matthew R. Smith, Sandy Srinivas, Przemyslaw Twardowski and Patrick C. Walsh
Prostate Cancer Clinical Practice Guidelines in Oncology NCCN Categories of Evidence and Consensus Category 1: The recommendation is based on high-level evidence (e.g., randomized controlled trials) and there is uniform NCCN consensus
Amit D. Raval, Suresh Madhavan, Malcolm D. Mattes, Mohamad Salkini and Usha Sambamoorthi
quality of care for non–cancer-related conditions. For example, among elderly men (age ≥66 years) with localized prostate cancer, the quality of care for acute chronic conditions is neglected. 3 Furthermore, among men of all ages with prostate cancer
Mark H. Kawachi, Robert R. Bahnson, Michael Barry, J. Erik Busby, Peter R. Carroll, H. Ballentine Carter, William J. Catalona, Michael S. Cookson, Jonathan I. Epstein, Ruth B. Etzioni, Veda N. Giri, George P. Hemstreet III, Richard J. Howe, Paul H. Lange, Hans Lilja, Kevin R. Loughlin, James Mohler, Judd Moul, Robert B. Nadler, Stephen G. Patterson, Joseph C. Presti, Antoinette M. Stroup, Robert Wake and John T. Wei
Prostate Cancer Early Detection Clinical Practice Guidelines in Oncology NCCN Categories of Evidence and Consensus Category 1: The recommendation is based on high-level evidence (e.g., randomized controlled trials) and there is uniform
Brandon R. Mason, James A. Eastham, Brian J. Davis, Lance A. Mynderse, Thomas J. Pugh, Richard J. Lee and Joseph E. Ippolito
Role of Multiparametric MRI in Diagnosis Conventional screening for prostate cancer (PCa) consists of digital rectal examination (DRE) and serum prostate-specific antigen (PSA) testing, followed by transrectal ultrasound (TRUS)–guided prostate
Lydia T. Madsen, Deborah A. Kuban, Seungtaek Choi, John W. Davis, Jeri Kim, Andrew K. Lee, Delora Domain, Larry Levy, Louis L. Pisters, Curtis A. Pettaway, John F. Ward, Christopher Logothetis and Karen E. Hoffman
An estimated 1 in 6 men in the United States will be diagnosed with prostate cancer in their lifetime. 1 Although progress has been made, much still needs to be done to improve the diagnosis, treatment, survival, and quality of life for this
Firas Abdollah, Jesse D. Sammon, Kaustav Majumder, Gally Reznor, Giorgio Gandaglia, Akshay Sood, Nathanael Hevelone, Adam S. Kibel, Paul L. Nguyen, Toni K. Choueiri, Kathy J. Selvaggi, Mani Menon and Quoc-Dien Trinh
Prostate cancer (PCa) is the most common noncutaneous cancer and the second leading cause of cancer-related death in North American men. 1 In the United States, 233,000 new cases of PCa are estimated to be diagnosed in 2014, along with 29,480 PCa
James L. Mohler, Emmanuel S. Antonarakis, Andrew J. Armstrong, Anthony V. D’Amico, Brian J. Davis, Tanya Dorff, James A. Eastham, Charles A. Enke, Thomas A. Farrington, Celestia S. Higano, Eric Mark Horwitz, Michael Hurwitz, Joseph E. Ippolito, Christopher J. Kane, Michael R. Kuettel, Joshua M. Lang, Jesse McKenney, George Netto, David F. Penson, Elizabeth R. Plimack, Julio M. Pow-Sang, Thomas J. Pugh, Sylvia Richey, Mack Roach III, Stan Rosenfeld, Edward Schaeffer, Ahmad Shabsigh, Eric J. Small, Daniel E. Spratt, Sandy Srinivas, Jonathan Tward, Dorothy A. Shead and Deborah A. Freedman-Cass
Overview An estimated 174,650 new cases of prostate cancer will be diagnosed in 2019, accounting for 20% of new cancer cases in men. 1 The age-adjusted death rates from prostate cancer have declined 51% from 1993 to 2016. 1 Researchers have
